AC Immune has been granted a patent for a liposomal vaccine composition designed to treat amyloid-beta associated diseases. The composition features a ß-amyloid-derived peptide antigen, a universal T-cell epitope, and an adjuvant, aimed at inducing protective immune responses and alleviating cognitive memory loss symptoms. GlobalData’s report on AC Immune gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AC Immune, Neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. AC Immune's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Liposomal vaccine for amyloid-beta associated diseases
The granted patent US12005102B2 outlines a novel liposomal vaccine composition designed to elicit an immune response against amyloid-beta (Aß)-associated diseases. The composition features a ß-amyloid-derived peptide antigen displayed on the surface of a liposome, alongside a peptide containing a universal T-cell epitope encapsulated within the liposome. This T-cell epitope is crucial for stimulating helper T-cell responses, which in turn enhance antibody production by B-cells. The patent specifies various configurations for the T-cell epitope, including specific amino acid sequences and combinations with immunogenic domains such as those from tetanus toxin and keyhole limpet hemocyanin (KLH). Additionally, the composition may include an adjuvant, which can be integrated into the liposome itself.
Further claims detail the structural characteristics of the T-cell epitopes, emphasizing their hydrophobic nature and potential combinations within the liposome. The patent allows for the inclusion of multiple T-cell epitopes, with specifications on their length and the use of linkers to connect them. Notably, the adjuvant can comprise monophosphoryl lipid A (MPLA), CpG, or both, enhancing the vaccine's efficacy. The patent also describes a kit for administering the vaccine, aimed at treating or preventing conditions associated with amyloid-beta. Overall, the claims present a comprehensive approach to developing a liposomal vaccine that targets amyloid-beta-related diseases through a sophisticated immunological strategy.
To know more about GlobalData’s detailed insights on AC Immune, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
